Alma Family Dentistry | |
612 South Street Alma NE 68920 | |
(308) 928-9010 | |
(308) 928-9031 |
Full Name | Alma Family Dentistry |
---|---|
Speciality | Dentist |
Location | 612 South Street, Alma, Nebraska |
Authorized Official Name and Position | Jesse M Neal (OWNER) |
Authorized Official Contact | 3089289010 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Alma Family Dentistry Po Box 807 Alma NE 68920-0807 Ph: (308) 928-9010 | Alma Family Dentistry 612 South Street Alma NE 68920 Ph: (308) 928-9010 |
NPI Number | 1447698667 |
---|---|
Provider Enumeration Date | 06/10/2013 |
Last Update Date | 06/10/2013 |
Identifier | Type | State | Issuer |
---|---|---|---|
1447698667 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
122300000X | Dentist | 6425 (Nebraska) | Primary |
News Archive
The Trump administration and drugmakers are squaring off over a proposal to show drug prices in television ads.
Regenerative medicine, or the use of specially grown tissues and cells to treat injuries and diseases, has been successful in treating disorders of a number of organs, including heart, pancreas, and cartilage. However, efforts to treat disorders of the corneal endothelium, a single cell layer on the inner surface of the cornea, with regenerative techniques have been less effective. Now, a group of scientists has developed a method that enhances the adhesion of injected corneal endothelial cells (CECs), allowing for successful corneal transplantation to repair pathological dysfunctions.
The National Marrow Donor Program today applauded the introduction of the "Stem Cell Therapeutic and Research Reauthorization Act of 2010." Sens. Orrin Hatch (R-UT), Christopher Dodd (D-CT), Richard Burr (R-NC), Jack Reed (D-RI), John Ensign (R-NV), and Al Franken (D-MN) introduced the act in the U.S. Senate as S. 3751 on Thursday, Aug. 5. Last evening, Reps. C.W. Bill Young (R-FL) and Doris Matsui (D-CA) introduced the companion legislation, (H.R. 6081), in the House.
Researchers at the UPM and CSIC, within the Cajal Blue Brain project, develop ESPINA, a new freeware software tool that allows to study the brain structure in greater depth.
Sanofi-aventis announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
› Verified 2 days ago